Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Sales of Lilly's top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year. The Danish pharmaceutical giant said sales of Wegovy ...